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The selectivity of certain benzophenones and their car-
bonyl N-analogues was investigated towards the human
GSTP1-1 allozymes A, B and C involved in MDR. The al-
lozymes were purified from extracts derived from E. coli
harbouring the plasmids pEXP5-CT/TOPO-TA-
hGSTP1*A, pOXO4-hGSTP1*B or pOXO4-hGSTP1*C.
Compound screening with each allozyme activity indi-
cated three compounds with appreciable inhibitory
potencies, 12 and 13 with P1-1A 62% and 67%, 11 and
12 with P1-1C 51% and 70%, whereas that of 15 fell
behind with P1-1B (41%). These findings were con-
firmed by IC50 values (74–125 lM). Enzyme inhibition
kinetics, aided by molecular modelling and docking,
revealed that there is competition with the substrate
CDNB for the same binding site on the allozyme (Ki(13/
A) = 63.6  3.0 lM, Ki(15/B) = 198.6  14.3 lM, and Ki(11/
C) = 16.5  2.7 lM). These data were brought into con-
text by an in silico structural comparative analysis of the
targeted proteins. Although the screened compounds
showed moderate inhibitory potency against hGSTP1-1,
remarkably, some of them demonstrated absolute iso-
enzyme and/or allozyme selectivity.
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Benzophenones, along with bioflavonoids, coumarins and
xanthones, constitute a major class of compounds
exhibiting multiple biological activities (1). o-Hydroxybenz-
ophenone derivatives, in particular, are ubiquitous in nat-
ure but also synthetically obtained compounds, for
example certain combretastatins and phenstatins (2). Our
recently reported interest in utilizing the reactivity profile
of xanthone (3) in synthesis (4,5), as well as its inhibitory
potential towards the medically important human isoen-
zyme glutathione transferase A1-1 (hGSTA1-1) (6),
prompted us to investigate xanthone ring-opened ana-
logues, substituted 2,20-o-dihydroxybenzophenones,
towards hGSTA1-1 (7), taking advantage of their struc-
ture similarities, in pursuit of promising inhibitor lead
structures against this enzyme, involved in multiple drug
resistance (MDR). To that end, GSTs (EC 2.5.1.18) are
cell-detoxifying agents, for they catalyse the coupling of
glutathione (GSH) to hydrophobic xenobiotic and endog-
enous compounds, rendering them hydrophilic and, thus,
facilitating their metabolic processing and eventual secre-
tion from the cell (8). Based on the same detoxification
mechanisms, cancer cells often acquire resistance by
overexpressing GSTs (9), hampering the effectiveness of
certain chemotherapeutic drugs. In particular, GSTs of
the p class are the most studied isoenzymes in human
cancer. Their expression levels vary with tumour type
and stage, hence affecting the effectiveness of anticancer
drugs, for example thiotepa and chlorambucil (10–12).
Therefore, certain GST-recognizing drugs and prodrugs
have been suggested to overcome MDR attributed to
GST overexpression (13–15). For example, the prodrug
TLK286 (Telcyta) is activated by hGSTP1-1, after being
triggered by Tyr7 located in the active region of the iso-
enzyme (16). As tumour-protective phenomena may vary
by patient GST isoenzyme/allozyme profiles, we thought
to study dihydroxybenzophenones and their carbonyl
N-analogues as inhibitors discriminating not only
between A1-1 and P1-1 hGST isoenzymes but also
between hGSTP1-1 allozymes A, B and C, involved in
MDR (17).
ª 2015 John Wiley & Sons A/S. doi: 10.1111/cbdd.12574 1055
Chem Biol Drug Des 2015; 86: 1055–1063
Research Article
Materials and Methods
Expression and purification of hGSTP1-1
allozymes
The expression was based on a published method with
modifications (18), whereas the enzyme purification
procedures were developed in our laboratory (Appendix
S1).
Routine enzyme assay for determining GST
activity
Determination of GST activity was performed by monitor-
ing the formation of the conjugate between CDNB and
GSH at 340 nm (e = 9600 L/mole/cm) at 6.5 and 25 °C.
One unit of enzyme activity is defined as the amount of
enzyme that produces 1.0 lmole of product per minute
under the assay conditions (7).
Compound screening as inhibitors for hGSTP1-1
allozymes (‘cherry picking’)
‘Cherry picking’ was performed by introducing the ingre-
dients in the following order (1 mL final assay volume):
potassium phosphate buffer (approx. 100 mM final, pH
6.5), CDNB (20 lL from 50 mM stock solution prepared
in ethanol; 1.0 mM final), test compound (20 lL from
5 mM stock solution in DMSO; 0.1 mM final) and enzyme
(typically, 80 lL from hGSTP1A producing 0.0370
DΑ340/min, 50 lL from hGSTP1B producing 0.0491
DΑ340/min and 35 lL from hGSTP1B (previously diluted
with buffer, 1:10 v/v) producing 0.0502 DΑ340/min). After
mixing, the reaction started by adding GSH (20 lL from
125 mM stock prepared in water; 2.5 mM final) and con-
tinued for 1 min at 25 °C. The observed rate was used
to calculate the remaining activity (%), taking as 100%
initial activity value the rate observed, after replacing the
test compound by an equal volume of DMSO which, in
all assays, was maintained at a 2% v/v final concentra-
tion.
Determination of IC50 values for inhibitors
selected from ‘cherry picking’
Initial velocities for the GST-catalysed reaction with
CDNB (1 mM) and GSH (2.5 mM) as substrates were
measured at 25 °C, in the presence of various concen-
trations of the inhibitors selected from ‘cherry picking’,
using the same assay conditions (see previous para-
graph). Different inhibitor quantities, in 20 lL DMSO,
were introduced in the assay mixture. The observed rate
was used to calculate the remaining activity (%), taking
as 100% initial activity value the observed rate, after
replacing the inhibitor by an equal volume of DMSO
(20 lL). The IC50 values were determined from a graph
depicting remaining GST activity (%) against inhibitor
concentration.
Kinetic analysis of inhibitors selected from ‘cherry
picking’
Initial velocities for the GST-catalysed reaction with CDNB
as variable substrate were determined in reaction mixtures
of a total volume of 1 mL (25 °C) containing potassium
phosphate buffer (100 mM, pH 6.5), 2.5 mM GSH and dif-
ferent concentrations of CDNB (60–2100 lM with
hGSTP1A, 75–2100 lM with hGSTP1B and 37.5–2100 lM
with hGSTP1C) in the absence and presence of inhibitor
13 (0, 25 and 50 lM with hGSTP1A) or inhibitor 15 (0, 40,
80 and 100 lM with hGSTP1B) or inhibitor 11 (0, 15, 30,
70 and 100 lM with hGSTP1C). Initial velocities for the
hGSTA1-1-catalysed reaction with GSH as variable sub-
strate were determined in reaction mixtures of a total vol-
ume of 1 mL (25 °C) containing potassium phosphate
buffer (100 mM, pH 6.5), 1 mM CDNB and different con-
centrations of GSH (45–2500 lM) in the absence and
presence of inhibitor 11 (0, 15, 30 and 60 lM).
Modelling and docking: the in silico structures of
hGSTPs and docking of the 2,20-
dihydroxybenzophenones and their carbonyl N-
analogues
The structure of hGSTP1-1 (variant or allozyme A) in com-
plex with ethacrynic acid and its glutathione conjugate
was downloaded from the Protein Data Bank (PDB code
11GS) and prepared with the Protein Preparation Wizard
(19) in Maestro (Schrodinger, LLC, New York, NY, USA).
Two further variants (allozymes B and C), according to
their amino acid substitutions in positions 104 and 113,
were constructed, using the X-ray structure of allozyme B
(PDB code 1PGT) and a constructed model for the mutant
of the external surface mutation Ala113Val, defining the
optimal rotamers of the respected side chains using
12 nseconds molecular dynamics on DESMOND 3.6 (20). Ro-
tamers were displayed with PyMOL (Figure S1). A docking
grid, including the tripeptide substrate glutathione, was set
up centred on ethacrynic acid (Table S1). OMEGA 2.5.1.4
(OpenEye Scientific Software) (21) was used to generate
molecular conformations of the synthetic analogues.
Potentially active compounds with a similar shape to
parental compounds were identified by ROCS 3.2.0.4 (22)
fast shape comparison application. The synthetic ana-
logues were docked flexibly using Glide SP (23,24) (Table
S1). Docking results (Table S2a,b,c) were both visually
inspected and quantitatively evaluated based on a docking
score. Docking results were checked for positional stability
using postdocking molecular dynamics with Desmond 3.6
(Table S3). All figures depicting 3D models were created
using PYMOL, version 1.7.4 (Schrodinger, LLC).
Results and Discussion
The hGSTP1 allozymes were purified on a GSH-affinity chro-
matography column (enzyme desorption with 10 mM GSH),
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leading to enzyme preparations of good purification charac-
teristics and overall protocol performance (Table S4).
Compound screening and selection of inhibitors
for hGSTP1-1
To reveal the enzyme inhibitory potency of the 2,20-dihydr-
oxybenzophenones and their carbonyl N-analogues, all
compounds were subjected to screening against the three
allozymes, hGSTP1A, hGSTP1B and hGSTP1C. In design-
ing the screening enzyme assay protocol against hGSTP1-
1, the concentration of 100 lM was chosen. This choice
was dictated by preliminary experiments run at concentra-
tions in the range 1–30 lM, as suggested in the literature
(7,25), showing the compounds not to be as effective
inhibitors with the P1-1 isoenzyme as they were with A1-1
(7). A more crucial factor to be decided has been the sub-
strate concentration, CDNB, in the enzyme inhibition assay
for ‘cherry picking’ and IC50 determinations. Having initially
considered the known Michaelis constant for the CDNB-
hGSTP1-1 couple (Km = 0.98  0.06 mM) (17), we per-
formed inhibition assays at [CDNB] = 1 mM, fulfilling the
so-called balanced assay conditions, that is [CDNB]  Km,
acknowledged in the literature as the optimum choice
(6,7,25). From the screening data obtained (Table 1, Fig-
ure S2), one distinguishes three groups of inhibitory
potency against the hGSTP1 allozymes (Table S5): <20%
(low inhibition), 20–40% (medium inhibition) and 50–80%
(high inhibition), using 100 lM of compound. A forth group
of ‘very high’ inhibition (>80%) is applicable only to isoen-
zyme hGSTA1-1, when using only 25 lM of compound
(Table S5). The compounds with the strongest inhibition
potency for hGSTP1-1 were further studied to determine
their IC50 values from concentration–response curves
(Figure 1, Table S6). Predictably, compounds with higher
% inhibition potency exhibited lower IC50 values. It appears
that the compounds are not, overall, as effective for
hGSTP1-1 inhibition, as for hGSTA1-1 (Table 1). However,
it is most interesting that some of them exhibited a clear
preference with respect to a particular isoenzyme. For
example, 6, 8, 9 and 15, although weak inhibitors for the
P1-1A allozyme at 100 lM (Table 1;  41%, 0%, 0% and
24%, respectively), are rather potent for isoenzyme A1-1
at only 25 lM ( 86%, 88%, 59% and 96%, respectively).
Even a more interesting behaviour is shown by certain
compounds that demonstrated absolute selectivity for spe-
cific isoenzymes and/or allozymes. For example, 6 and 7,
the 5-mono- and 5,50-di-phenyl-substituted benzophenon-
es, show absolute selectivity for A1-1 over the P1-1B allo-
zyme (Table 1;  86% and 34% versus 0%, respectively),
whereas additional absolute selectivity for A1-1 is shown
by 7 over the P1-1C allozyme. In practice, 6 is also selec-
tive for A1-1 over the P1-1B allozyme ( 86% versus
3.0%, respectively). Likewise, 8 and 9, the 5-mono- and
5,50-di-brominated benzophenones, show absolute selec-
tivity for A1-1 over P1-1A (Table 1;  88% and 59% ver-
sus 0%, respectively), whereas additional absolute
selectivity for A1-1 is shown by 8 over the P1-1B allozyme
and by 9 over the P1-1C allozyme. Even 15 can practically
be regarded as one of absolute selectivity with hGSTA1-1
(96% inhibition) over hGSTP1-1C (14% inhibition), as the
latter is diminished at 25 lM. On the other hand, 11, 12
and 13 show numerically comparable inhibitory potencies
with A1-1 and P1-1 (Table 1; 11: 52% versus 31%; 12:
68% versus 67%; 13: 87% versus 62%), thus being ade-
quate inhibitors for both isoenzymes, nevertheless still
more potent with hGSTA1-1. On the basis of these obser-
vations, we went on to investigate further the modality of
interaction between the most potent inhibitors and the tar-
get hGSTP1 allozymes by means of inhibition kinetics and
in silico molecular modelling and docking. Moreover, to
have a better understanding of the behaviour of these
compounds with isoenzymes A1 and P1, we brought into
context an in silico comparative approach for the proteins
under study.
Kinetics of hGSTP1-1 inhibition by selected
inhibitors
From the most potent inhibitors, we selected for enzyme
inhibition kinetics those structures exhibiting distinctive
chemical differences: a ketoxime (11), an aromatic N-acyl
hydrazone (13) and an aliphatic N-acyl hydrazone (15).
When using CDNB as a variable substrate, all compounds
displayed purely competitive inhibition kinetics on the basis
of the linearity observed for both the double-reciprocal Li-
neweaver–Burk graphs (Figures 2A and S3a,b) and their
respective secondary derivatives (Figures 2B and S3d,e)
(26,27), at various steady inhibitor concentrations. This
behaviour suggests that each of the inhibitors competes
with CDNB for the same binding site of the respective allo-
zyme: calculated inhibition constants Ki(13/A) =
63.6  3.0 lM (from Figure S3d), Ki(15/B) =
198.6  14.3 lM (from Figure S3e) and Ki(11/C) = 16.5
 2.7 lM (from Figure 2B). Predictably, with GSH as a vari-
able substrate, a mixed inhibition kinetics was observed,
manifested by the lines of the double-reciprocal Linewe-
aver–Burk graph of initial velocities versus [GSH], at various
steady inhibitor concentrations (i.e. compound 11), inter-
secting left of the reciprocal velocity axis (Figure S4a)
(26,27). Furthermore, the linear correlation of the respective
secondary derivative, depicting slope versus [inhibitor] (Fig-
ure S4b), is supportive of a purely mixed type of inhibition
(26,27). This equilibrium model predicts that the inhibitor
binds to both the free enzyme and the enzyme–GSH com-
plex, without product formation (26,27), interacting at a site
other than the GSH-binding site, that being partly the cata-
lytic CDNB-binding site, as shown earlier (Figure 2A,B).
Interestingly, the same kinetic modality (e.g. purely competi-
tive) had been observed earlier with 13 and hGSTA1-1, dis-
playing, nonetheless, a substantially higher inhibitory
potency (167-fold), Ki(13) = 0.38  0.05 lM (7) as com-
pared to 63.6  3.0 lM with hGSTP1-1. On the other hand,
the potency of compound 15, which was shown earlier to
have a different inhibition modality with hGSTA1-1 (mixed
hyperbolic) (7), is  113-fold higher with hGSTA1-1, com-
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Table 1: Some properties of 2,20-dihydroxybenzophenones and their carbonyl N-analogues. 5-9, ketones; 10-12, ketoximes; 13-15,
N-acyl hydrazones. hGSTP1A, Ile104/Ala113; hGSTP1B, Val104/Ala113; hGSTP1C, Val104/Val113
Compound no
and structure
Molecular
formula
Molecular
weight
hGSTP1A
inhibition (%)a
hGSTP1B
inhibition (%)a
hGSTP1C
inhibition (%)a
hGSTA1-1
inhibition (%)b
5
OOH OH
C13H10O3 214 26.8  3.4 12.4  2.3 25.0  4.6 –
6
OOH OH
C19H14O3 290 41.3  0.7 – 3.0  4.7 86.1
7
OOH OH
C25H18O3 366 1.5  4.0 – – 33.9
8
OOH OH
Br
C13H9BrO3 293 – – 19  3.5 87.7
9
OOH OH
Br Br
C13H8Br2O3 372 – 11.0  1.9 – 58.6
10
NOHOH OH
C13 H11 N O3 229 17.0  3.3 – 21.4  0.8 40.5
11
NOHOH OH
Br
C13H10BrNO3 308 31.0  4.7 23.0  5.0 50.7  5.0 52.3
12
NOHOH OH
C19H15NO3 305 67.0  4.6 37.7  1.9 70.1  1.3 67.7
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pared with hGSTP1-1, Ki(15) 1.75 (7) versus 198.6 lM,
respectively. Regardless of the different inhibition modality
observed, both 13 and 15 are significantly weaker with the
P1-1 isoenzyme, compared to A1-1. Taking into consider-
ation the earlier discussion on the inhibition potency and the
findings from the kinetics study, one can conclude that the
compounds are directed to the H-site of the enzyme but
with a varying selectivity for the particular isoenzyme, A1-1
and P1-1. Molecular modelling, docking and structural com-
parison studies may clarify certain aspects of this behaviour.
Molecular modelling and docking: in silico study of
the selected inhibitors with hGSTA1-1 and
hGSTP1-1 allozymes
Three allelic variants of hGSTP1-1 (variant A PDB code
11GS, variant B PDB code 1PGT), containing an Ile104-
Val or Ala113Val substitution or a combination of both,
have been studied for in silico binding together with
hGSTA1-1 (PDB code 1GSE) and showed different inter-
action parameters.
In regard to the differences between hGSTA1-1 and
hGSTP1-1, it is apparent that the binding site of the former
is much wider due to the shift of the C-terminal eleven amino
acid residues (res 210–221 in hGSTA1 forming an a-helix,
whereas res 201–207 in hGSTP1-1 forming a closed loop)
(Figure 3). Although the binding site of hGSTP1-1 remains
essentially the same from three sides, on the fourth (upper)
side, the flexible C-terminal structure in hGSTP1-1 diminishes
the binding site volume. Hence, compounds bound in
hGSTP1-1 have to occupy a more restricted site, reducing
possible modes of binding and affecting interactions (Fig-
ures 4 and S5). This is in agreement with the findings from
the screening experiments (Table 1) and the earlier discus-
sion (cf. % inhibition with hGSTA1-1 versus hGSTP1-1).
As to the hGSTP1-1 allozymes, the in silico binding results
show that the mutation between the allozymes A, B and C
of the amino acid side chain at residue position 104 is
ligand dependent. Indeed, in accord with the available
crystal structures of hGSTP1*A, hGSTP1*B and
hGSTP1*C (28,29), position 104 is localized in the H-site
Table 1: continued
Compound no
and structure
Molecular
formula
Molecular
weight
hGSTP1A
inhibition (%)a
hGSTP1B
inhibition (%)a
hGSTP1C
inhibition (%)a
hGSTA1-1
inhibition (%)b
13
NOH OH
NH
CO
C20H16N2O3 332 61.7  4.2 30.7 0  0.2 29.6  1.7 87.4
14
NOH OH
NH
CO
N
C19H16N3O3 334 17  2.2 21.8  1.6 18.0  0.7 31.8
15
NOH OH
NH
CO
CH3
Br
C15H13BrN2O3 349 24.2  4.8 40.7  0.2 14.0  5.0 96.1
aThe errors shown were based on three assays.
bData taken from reference 7 (mean values of three assays; 25 lM compound, error ≤5%).
(–) No enzyme inhibition was observed.
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of hGSTP1-1 and can affect enzyme activity in several
ways dependent on the ligand (30). The Ile104Val mutation
affects the shape of the active site (Figure 4B) because
Val104 occupies a smaller volume than Ile104, allowing
the accommodation of larger ligands (28). Also, residue
104 is close to the functional residue Tyr108, important in
the catalytic mechanism of hGSTP1-1 by stabilizing the
intermediate complex (31,32). In addition, mutation Ile104-
Val has shown to alter the hydrophobicity/hydrophilicity
status of the H-site of hGSTP1-1 by influencing the num-
ber of active-site water molecules that can interact during
substrate binding and/or product release (32,33). These
factors explain, in part at least, the selectivity of the com-
pounds between hGSTA1-1 and hGSTP1-1 isoenzymes
as well as between the hGSTP1-1 allozymes. Benzophe-
none analogues containing a hydrophobic moiety (e.g.
phenyl ring) at position 5 are shown to optimally bind dif-
ferently in hGSTA1-1 (Figure 4B, ligands in blue) and in
hGSTP1-1 (Figure 4B, ligands in green for allozyme A and
in red for allozymes B and C), the former isoenzyme not
exposing the hydrophobic group to solvent, while the latter
with a more open binding site having larger exposure to
solvent. There are also differences in binding between
hGSTP1-1 allozymes A and B,C, with A having ligands
bound deeper in the pocket (Figure S6, green ligands) with
reduced exposure of the ligand’s hydrophobic groups,
compared to B and C (Figure S6, red ligands). This is in
agreement with the observation that all aryl-substituted
compounds (6,12,13) show a stronger inhibition with
hGSTP1-1A than the hGSTP1-1B,C allozymes (Table 1).
However, the diaryl-substituted 7 fails to bind effectively to
any of the three hGSTP1-1 allozymes, due to the size and
character (hydrophobic) of the substituting groups in the
restricted polar binding site volume. Interestingly, the deriv-
atization of the benzophenone carbonyl group (ketoximes
10-12, Figure S7a) and N-acyl hydrazones (13–15, Fig-
ure S7b) enhances the inhibition potency towards the allo-
zymes (Table 1), possibly due to the formation of at least
one hydrogen bond and reorientation of the compound in
the binding pocket. This behaviour probably indicates an
alternative (flipped) orientation in the enzyme-binding site.
Furthermore, from the in silico study, it is apparent that the
mode of binding to the P1-1 allozymes changes when
compounds become amphipathic with the introduction of a
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Figure 1: (A) Concentration–response graph for the determination
of the IC50 value for inhibitor 11 with hGSTP1-1C. The
‘concentration’ values (lM) are presented on logarithmic scale,
whereas the ‘response’ values (as % ratios of inhibited over
uninhibited rates) are presented on the ‘Remaining activity’ axis. The
graph was produced using GraFit3. The IC50 values determined
from such graphs for inhibitors 11, 12, 13 and 15 are given in (B).
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Figure 2: Purely competitive inhibition kinetics of allozyme
hGSTP1-1C with inhibitor 11 using CDNB as a variable substrate.
(A) Lineweaver–Burk graph of initial velocities versus [CDNB] at
different concentrations of 11 (○ 0, □ 15, ■ 30, D 70 and ●
100 lM). (B) Secondary graph for inhibitor 11 derived from data of
primary graph (A). The inhibition constant Ki is the intercept on the
basis axis of the secondary graph (B). Points are average of three
enzyme assays. The graphs were produced using GRAFIT3.
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bromine atom at position 5 (6 versus 8, Figure S8a; 11
versus 12, Figure S8b) but not at both positions 5 and 50 (7
and 9). This is in line with the observed differences in inhibi-
tion potency against the hGSTP1-1 allozymes (Table 1).
Conclusion
(i) There is no uniform binding mode of the compounds in
hGSTA1-1- and hGSTP1-1-binding sites but rather
specific modes related to their substitution (i.e. phenyl or
bromine groups) or carbonyl-derivatization pattern; (ii)
disubstituted benzophenones (at positions 5 and 50) lose
almost entirely their inhibition potency towards hGSTP1-1,
compared to a fairly strong inhibitory potency towards
hGSTA1-1, thus displaying isoenzyme specificity (A1-1
versus P1-1); (iii) monosubstituted benzophenones (at
position 5) lose entirely their inhibition potency towards
certain hGSTP1-1 allozymes and retain it towards others,
thus displaying remarkable absolute allozyme specificity
(P1-1A versus P1-1B versus P1-1C); and (iv) the derivati-
zation on the carbonyl carbon for obtaining ketoximes and
N-acyl hydrazones enhances their inhibition potency
towards hGSTP1-1.
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Dynamics Simulation parameters.
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their inhibition potency against human hGST isoenzymes
A1-1 and P1-1.
Table S6. Determined IC50 values for the stronger inhibi-
tors against hGSTP1-1 allozymes A, B and C.
Figure S1. Molecular dynamics on the hGSTP1-1 allo-
zyme B. The results of a 12 ns run on Desmond 3.6 are
displayed every 50 frames (0.24 ns) in different colours
using PyMOL. Only the backbone is shown in cartoon
mode with the Ile104 side chain shown in line mode to
indicate the rotamers.
Figure S2. Histogram presenting the relative inhibitory
potency of the compounds tested against hGST isoen-
zymes P1-1 and A1-1.
Figure S3. Purely competitive inhibition kinetics of
hGSTP1-1 with inhibitors 13, 15 and 11 using CDNB as a
variable substrate.
Figure S4. Mixed inhibition kinetics of hGSTP1-1 with
inhibitor 11 using GSH as a variable substrate.
Figure S5. Structural superposition between hGSTA1-1,
and hGSTP1-1 allozymes A and B with clustering of com-
pound 12 optimal binding positions.
Figure S6. Structural superposition between hGSTP1-1
allozyme A and allozymes B,C with clustering of com-
pound 6 optimal binding positions.
Figure S7. Optimal binding positions for ketoximes (10,
11, 12) and N-acyl hydrazones (13, 14, 15) on the
hGSTP1-1 allozyme A.
Figure S8. Optimal binding positions for 2,20-dihydroxy-
benzophenones 6 and 8, and for the respective ketoximes
11 and 12 on hGSTP1-1 allozyme A.
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